These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35192155)

  • 1. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
    Noiret B; Bakrin N; Eveno C
    Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Comment on ''Cytoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial''.
    Carneiro VCG; Ramalho NM
    Ann Surg Oncol; 2022 May; 29(5):3351-3352. PubMed ID: 35166953
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
    Cascales Campos PA; González Gil A
    Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
    Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    Xia Y; Wang H; Zhang J; Wang Y
    Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
    Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
    J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
    Aronson SL; Lopez-Yurda M; Koole SN; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van Gent MDJM; Arts HJG; van Ham MAPC; van Dam PA; Vuylsteke P; Aalbers AGJ; Verwaal VJ; Van de Vijver KK; Aaronson NK; Sonke GS; van Driel WJ
    Lancet Oncol; 2023 Oct; 24(10):1109-1118. PubMed ID: 37708912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01).
    Kim JH; Lee DE; Lee Y; Ha HI; Chang YJ; Chang SJ; Park SY; Lim MC
    J Gynecol Oncol; 2022 Jul; 33(4):e54. PubMed ID: 35712968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2).
    Gregory SN; Ryan CE; Hernandez JM; Sonke GS; Aronson SL; Zivanovic O; van Driel WJ;
    Ann Surg Oncol; 2023 Apr; 30(4):1950-1952. PubMed ID: 36581719
    [No Abstract]   [Full Text] [Related]  

  • 11. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
    Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
    J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: a Canadian experience.
    Neveu J; Tremblay E; Mercier F; Garneau S; Cormier B
    Int J Gynecol Cancer; 2023 Dec; 33(12):1957-1965. PubMed ID: 38011988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
    Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
    Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
    Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    Kim SI; Kim JW
    ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
    Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.
    Ronsini C; Pasanisi F; Greco P; Cobellis L; De Franciscis P; Cianci S
    Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984422
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?
    Praiss AM; Moukarzel LA; Zivanovic O
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):21-26. PubMed ID: 36595646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
    Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.